- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 14.04. | ELICERA THERAPEUTICS: Green light to continue Elicera's CARMA-trial in B-cell lymphoma | 2 | Cision News | ||
| 10.04. | Elicera Therapeutics AB: Elicera Therapeutics continues the Phase I/IIa CARMA study with its CAR T-cell therapy as planned following the safety committee's assessment of cohort 1 | 165 | GlobeNewswire (Europe) | Gothenburg, April 10, 2025 - Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next generation cancer treatments based on oncolytic viruses and CAR T-cell therapies... ► Artikel lesen | |
| 20.03. | Elicera Therapeutics resolves on a compensation issue to underwriters in connection with the completed exercise period for warrants of series TO2 | 3 | Cision News | ||
| 13.03. | Warrants of series TO2 in Elicera Therapeutics AB were subscribed to approximately 96.3 percent and the company resolves on a directed issue to underwriters | 1 | Cision News | ||
| 07.03. | The last day of trading with the warrants of series TO2 in Elicera Therapeutics is today, March 7, 2025 | 2 | Cision News | ||
| 03.03. | ELICERA THERAPEUTICS: Elicera's CEO: "TO2 is a highly attractive opportunity to increase ownership in Elicera" | 2 | Cision News | ||
| 28.02. | Correction: Board members and the executive management exercise warrants of series TO2 in Elicera Therapeutics | 2 | Cision News | ||
| ELICERA THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 28.02. | Board members and the executive management exercise warrants of series TO2 in Elicera Therapeutics | 1 | Cision News | ||
| 26.02. | Elicera Therapeutics - Positioned to deliver in cell and gene therapies | 286 | Edison Investment Research | Elicera Therapeutics is a cell and gene therapy company utilising its iTANK platform to develop immunotherapies for solid and bloodborne tumours. Its pipeline comprises two CAR-T therapies and two oncolytic... ► Artikel lesen | |
| 25.02. | Elicera Therapeutics has secured 100 percent of the warrants of series TO2 corresponding to approximately SEK 22.0 million | 1 | Cision News | ||
| 25.02. | The exercise price for the warrants of series TO2 in Elicera Therapeutics has been determined to SEK 1.85 | 2 | Cision News | ||
| 12.02. | Elicera Therapeutics receives partial payment of 0,5 MEur from EIC | 3 | Cision News | ||
| 12.02. | Elicera Therapeutics Receives Notification of Partial Payment of EUR 500,000 from the European Innovation Council Accelerator Programme | 2 | Cision News | ||
| 10.02. | Elicera Therapeutics Presents Initial Clinical Data from the CARMA Study at ISCT 2025 in New Orleans | 8 | Cision News | ||
| 05.02. | ELICERA THERAPEUTICS: Elicera's CEO: "2025 is a crucial year for us" | 1 | Cision News | ||
| 03.02. | Elicera Therapeutics AB: Elicera Therapeutics AB (publ) Year-end Report 1 January - 31 December 2024 | 102 | GlobeNewswire (Europe) | Fourth quarter (October-December 2024)
Operating profit/loss amounted to SEK -2,911,958 (-5,212,694).
Loss for the period amounted to SEK -2,603,242 (-4,749,222).
Cash flow from operating activities... ► Artikel lesen | |
| 28.01. | ELICERA THERAPEUTICS: Elicera's CEO: "All signs of the disease disappeared in the first patient" | 1 | Cision News | ||
| 21.01. | Elicera Therapeutics presents first clinical results from iTANK-armed CAR T-cell therapy at scientific conference | 2 | Cision News | ||
| 15.01. | ELICERA THERAPEUTICS: Elicera's candidate ELC-100 granted Orphan Drug Designation | 4 | Cision News | ||
| 13.01. | Elicera Therapeutics' drug candidate ELC-100 receives Orphan Drug Designation in the U.S. for the treatment of pancreatic neuroendocrine tumors | 2 | Cision News |
Seite:
1 2 Weiter >>
28 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 7,382 | +0,52 % | Aktien KW 16 Erholung. Aber: Death Cross als Crash-Menetekel? Oder gibt's Hoffnung? News. Rheinmetall. Kontron. Evotec. Nvidia. Hamborner REIT. MHP Hotels. Forvia Hella. Hensoldt. Circus. Berentzen. Fortec. Carl Zeiss MediTec. Drägerwerk. Agnicio Mining | Aktien Wochenrückblick - die Märkte scheinen sich langsam an die Zitterphase zu gewöhnen. Aktuelle Kurserholung dauerhaft? Oder was kommt noch: Zollankündigung, Handelskrieg mit China, 90 Tage Moratorium... ► Artikel lesen | |
| REGENERON PHARMACEUTICALS | 527,20 | -0,57 % | Regeneron Pharma Partners With FujiFilm Diosynth To Boost Capacity At $3 Bln Investment | WASHINGTON (dpa-AFX) - Regeneron Pharma, Inc. (REGN), a biotechnology company, on Tuesday announced a major expansion of its manufacturing capacity through a new agreement with FujiFilm Diosynth... ► Artikel lesen | |
| BRAIN BIOTECH | 2,290 | -2,55 % | EQS-News: BRAIN Biotech AG: Ergebnisse der Hauptversammlung 2025 zum Finanzjahr 2023/24 der BRAIN Biotech AG | EQS-News: BRAIN Biotech AG
/ Schlagwort(e): Hauptversammlung
Ergebnisse der Hauptversammlung 2025 zum Finanzjahr 2023/24 der BRAIN Biotech AG
18.03.2025 / 16:45 CET/CEST
Für... ► Artikel lesen | |
| SCORPIUS | 0,050 | 0,00 % | Scorpius Holdings, Inc.: Scorpius Holdings Receives NYSE American Notice of Delisting and Reports Plans to Appeal | San Antonio, TX, April 21, 2025 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX) ("Scorpius" or "the Company"), an integrated contract development and manufacturing organization ("CDMO")... ► Artikel lesen | |
| CARDIOL THERAPEUTICS | 0,950 | +0,85 % | Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research GmbH): Buy | Original-Research: Cardiol Therapeutics Inc - from First Berlin Equity Research GmbH 23.04.2025 / 15:24 CET/CEST Dissemination of a Research, transmitted by EQS News - a service of EQS Group. The... ► Artikel lesen | |
| BURCON NUTRASCIENCE | 0,056 | 0,00 % | Burcon NutraScience Corporation: Burcon Integrates Protein Technologies at Galesburg Facility | Vancouver, British Columbia--(Newsfile Corp. - April 1, 2025) - Burcon NutraScience Corporation (TSX: BU) (OTCQB: BRCNF) ("Burcon" or the "Company"), a global technology leader in the development of... ► Artikel lesen | |
| CSL | 138,12 | +0,42 % | CSL Behring und GKV-Spitzenverband einigen sich auf Erstattungspreis für HEMGENIX® - Europas erste Gentherapie für Hämophilie B | Marburg (ots) - CSL Behring und der GKV-Spitzenverband haben die Verhandlungen über den Erstattungspreis von HEMGENIX® erfolgreich abgeschlossen. Damit steht die erste in Europa zugelassene Gentherapie... ► Artikel lesen | |
| MANNKIND | 4,162 | -0,12 % | MannKind Corp. Q4 Earnings Summary | WASHINGTON (dpa-AFX) - Below are the earnings highlights for MannKind Corp. (MNKD):Earnings: $7.42 million in Q4 vs. $1.40 million in the same period last year.
EPS: $0.03 in Q4 vs. $0.00... ► Artikel lesen | |
| OXFORD NANOPORE TECHNOLOGIES | 1,426 | +0,71 % | Oxford Nanopore Technologies: Breakthrough algorithm enables partially phased, near telomere-to-telomere assembly using standard Oxford Nanopore Simplex reads | New hifiasm-ONT assembly method delivers high-quality, cost-efficient near T2T assemblies using standard Oxford Nanopore Simplex reads, broadening access to comprehensive genome assemblies across... ► Artikel lesen | |
| OCULAR THERAPEUTIX | 6,866 | +1,09 % | Ocular Therapeutix, Inc.: Ocular Therapeutix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | BEDFORD, Mass., April 11, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, "Ocular"), a biopharmaceutical company committed to redefining the retina experience, today announced that... ► Artikel lesen | |
| ADAPTIMMUNE THERAPEUTICS | 0,250 | +5,93 % | Adaptimmune Therapeutics PLC: Adaptimmune Provides Q4 and Full Year 2024 Business Update | TECELRA® launch momentum accelerating - 10 patients apheresed in Q1 2025 and 3 in 2024; 20 ATCs available; all manufacturing and supply goals achievedLete-cel on track to initiate rolling BLA submission... ► Artikel lesen | |
| CODEXIS | 2,000 | +0,86 % | Codexis Aktie: Folgenschwere Entwicklung? | Die Codexis Aktie verzeichnete am 22. März 2025 einen leichten Anstieg von 1,94% und schloss bei 2,36 EUR. Diese positive Entwicklung kommt nach einem schwierigen Monat, in dem das Biotechnologieunternehmen... ► Artikel lesen | |
| TELO GENOMICS | 0,056 | 0,00 % | Telo Genomics Corp.: Telo Genomics Announces Acceptance of its MRD Validation Data in Multiple Myeloma for ASCO 2025 | Toronto, Ontario--(Newsfile Corp. - April 10, 2025) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo"), a leader in the development of diagnostic and prognostic tests for human... ► Artikel lesen | |
| BIORA THERAPEUTICS | 1,260 | -100,00 % | Biora Therapeutics, Inc.: Biora Therapeutics Undertakes Chapter 11 Sale Process to Position Business for Future Growth | Sale process will help enable next stage of product development Secures up to $10.25 million in new financing to support ongoing business operations SAN DIEGO, Dec. 30, 2024 (GLOBE NEWSWIRE) -- Biora... ► Artikel lesen | |
| CORMEDIX | 8,050 | +0,62 % | CorMedix Inc. - 8-K, Current Report |
Das Unternehmen ELICERA THERAPEUTICS AB kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,034 (+11,69 %) liegt der Kurs bei 0,320 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ELICERA THERAPEUTICS AB finden Sie auf Wallstreet Online.
